|
C14ORF33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.19290133326899E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.60169655316622E-11 |
| Normal-vs-Stage2 |
1.564970E-03 |
| Normal-vs-Stage3 |
2.63045141224438E-12 |
| Normal-vs-Stage4 |
6.33937347060964E-14 |
| Stage1-vs-Stage2 |
1.295770E-02 |
| Stage1-vs-Stage3 |
1.708600E-01 |
| Stage1-vs-Stage4 |
1.066470E-02 |
| Stage2-vs-Stage3 |
2.678800E-03 |
| Stage2-vs-Stage4 |
3.976300E-04 |
| Stage3-vs-Stage4 |
2.751800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.94551058491288E-12 |
| Normal-vs-AfricanAmerican |
2.8082000003149E-07 |
| Normal-vs-Asian |
1.38869999943836E-08 |
| Caucasian-vs-AfricanAmerican |
9.534400E-01 |
| Caucasian-vs-Asian |
1.870590E-01 |
| AfricanAmerican-vs-Asian |
3.397400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.27331478694259E-12 |
| Normal-vs-Female |
5.93503024504116E-12 |
| Male-vs-Female |
3.508800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.33659749934623E-11 |
| Normal-vs-Age(41-60Yrs) |
1.3502976514701E-11 |
| Normal-vs-Age(61-80Yrs) |
7.27430338187673E-11 |
| Normal-vs-Age(81-100Yrs) |
1.952930E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.935800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.845200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.477200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.319600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.184800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.182800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.38310000000497E-05 |
| Classical-VS-Follicular |
7.824100E-04 |
| Classical-VS-Other |
3.760000E-01 |
| Classical-VS-Normal |
4.73521222232876E-12 |
| Tall-VS-Follicular |
7.70480002021401E-09 |
| Tall-VS-Other |
1.044650E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
8.506000E-01 |
| Follicular-VS-Normal |
4.67929999969918E-07 |
| Other-VS-Normal |
5.581900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.29816166097407E-14 |
| Normal-vs-N1 |
1.28230759344206E-13 |
| N0-vs-N1 |
2.260400E-03 |
|
|
